Home > Chemicals & Materials > Advanced Materials > Drug Integrated Polymer Fibers Market
Orthopedics was the largest market for drug integrated polymer fibers in 2017 and is expected to grow at a faster rate as compared to other applications during the forecast period. The market size of drug integrated polymers fibers which consists of PLA, PCL, PDO, PLGA, PGA used in orthopedics application was estimated at USD 16.33 million in 2017 and is expected to grow at a 7.6% CAGR annually. Aging population is the major driver for orthopaedic sutures applications. Drug delivery is also one of the fastest growing application for drug integrated polymer fibers, which is estimated to grow at a healthy CAGR during the forecast period.
The report includes market analysis of different types of biodegradable fibers such as polylactic acid, polydioxanone, polycaprolactone, polyglycolic acid, poly(lactic-co-glycolic acid) and other copolymers used in different implantable medical applications. Polylactic acid and its derivatives accounted for the largest share in the drug integrated polymer fibers market driven by stable biodegradability and biocompatibility of this materials. PLA accounted for almost 48% of the total market and was estimated at USD 25.48 million in 2017 growing at a CAGR of 6.7% till the forecast period.
Polydioxanone was the second largest market of drug integrated polymer fibers in 2017 accounting for almost 18% of the market share.
Geographically, North America is estimated to be the largest market of drug integrated polymer fibers market accounting for almost 55% share in 2017. Rise in old population and increase in lifestyle diseases such as obesity and others will help maintain North America retain its share till forecast period.
Europe drug integrated polymer fibers market size was more than USD 14.08 million by 2017 and is estimated to grow at a steady rate. Rising demand and awareness from developing countries particularly Eastern Europe will fuel the growth of drug integrated polymer fibers.